After Alchemab's completion of pre-clinical tasks as part of a previous licensing agreement with Eli Lilly and Company for ATLX-1282, they secured funding with contributions from Eli Lilly and Company and Ono Venture Investment. The financial support also included significant backing from renowned entities.